|Molar Mass||246.310 g·mol−1|
Nefiracetam Powder represents a dedicated research product developed exclusively for scientific exploration, with a clear demarcation from any association with human consumption. These powders serve as a valuable tool for researchers investigating the unique properties and potential benefits of nefiracetam in various research domains.
Nefiracetam is a member of the racetam class of nootropics, recognized for its potential cognitive-enhancing properties. It has garnered attention for its pharmacological characteristics and its impact on various aspects of cognitive function.
Nefiracetam Powder finds diverse applications in research domains, offering researchers a tool to explore the potential benefits of nefiracetam. Its applications extend to investigations into cognition enhancement, depression, and visual acuity.
Nefiracetam and Cognition Enhancement
Studies suggest that nefiracetam may have potential cognitive-enhancing effects, particularly in the domains of memory and learning. Research in this domain aims to uncover the mechanisms of action and potential applications in addressing cognitive deficits.
Nefiracetam and Depression
Preliminary research indicates that nefiracetam may have antidepressant properties, potentially influencing mood regulation. Investigations into its effects on depressive symptoms contribute to understanding its potential applications in addressing mood disorders.
Nefiracetam and Visual Acuity
Research suggests that nefiracetam may impact visual acuity and perception. Studies exploring its effects on visual function contribute to understanding its potential applications in vision-related research.
Nefiracetam Powder, tailored exclusively for research purposes, provides researchers with a unique avenue for investigating the potential benefits of nefiracetam in cognition enhancement, depression, and visual acuity. The distinctive characteristics of nefiracetam make it a promising subject for further exploration in neuroscientific and psychological research.
- Yamada, K., Tanaka, T., Mamiya, T., Shiotani, T., Kameyama, T. and Nabeshima, T. (1999), Improvement by nefiracetam of β-amyloid-(1-42)-induced learning and memory impairments in rats. British Journal of Pharmacology, 126: 235-244. https://doi.org/10.1038/sj.bjp.0702309 [Read More].
- Double-Blind Randomized Treatment of Poststroke Depression Using Nefiracetam. Robert G. Robinson M.D.Ricardo E. Jorge M.D.Kathleen Clarence Smith M.D., Ph.D. Published Online:1 Apr 2008. [Read More].